Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events.
Jokimäki A, Hietala H, Lemma J, Karhapää H, Rintala A, Kaikkonen JP, Sunela K, Boman E, Jukkola A, Tiainen S, Seppälä J, Rönkä A, Hakkarainen H, Kärnä A, Iivanainen S, Koivunen J, Auvinen P, Hernberg M, Kuusisto M, Selander T, Kuittinen O. Jokimäki A, et al. Among authors: ronka a. Cancer Immunol Immunother. 2023 Oct;72(10):3337-3347. doi: 10.1007/s00262-023-03494-4. Epub 2023 Jul 24. Cancer Immunol Immunother. 2023. PMID: 37486396 Free PMC article.
Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020.
Harmanen M, Hujo M, Sund R, Sorigue M, Khan M, Prusila R, Klaavuniemi T, Kari E, Jantunen E, Sunela K, Rajamäki A, Alanne E, Kuitunen H, Sancho JM, Jukkola A, Rönkä A, Kuittinen O. Harmanen M, et al. Among authors: ronka a. Br J Haematol. 2023 Apr;201(1):64-74. doi: 10.1111/bjh.18597. Epub 2022 Dec 13. Br J Haematol. 2023. PMID: 36513500
Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy.
Vihinen H, Jokinen A, Laajala TD, Wahid N, Peltola L, Kettunen T, Rönkä A, Tiainen L, Skyttä T, Kohtamäki L, Tulokas S, Karhapää H, Hernberg M, Silvoniemi M, Mattila KE. Vihinen H, et al. Among authors: ronka a. Clin Lung Cancer. 2023 Jun;24(4):295-304. doi: 10.1016/j.cllc.2023.01.004. Epub 2023 Jan 24. Clin Lung Cancer. 2023. PMID: 36774235 Free article.
Blood-Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study.
Kuitunen HK, Rönkä ALK, Sonkajärvi EM, Isokangas JM, Pyörälä M, Palosaari KAA, Jokimäki AS, Partanen AE, Littow HJ, Vakkala MA, Jantunen EJ, Huttunen ME, Marin KJ, Aromaa-Häyhä AMK, Auvinen PK, Selander T, Puhakka IK, Kuittinen OM. Kuitunen HK, et al. Among authors: ronka alk. Cancers (Basel). 2023 Feb 20;15(4):1341. doi: 10.3390/cancers15041341. Cancers (Basel). 2023. PMID: 36831682 Free PMC article.
The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + and CD8 +) and tumor-associated macrophages in early HER2 + breast cancer.
Jääskeläinen MM, Tiainen S, Siiskonen H, Ahtiainen M, Kuopio T, Rönkä A, Kettunen T, Hämäläinen K, Rilla K, Harvima I, Mannermaa A, Auvinen P. Jääskeläinen MM, et al. Among authors: ronka a. Breast Cancer Res Treat. 2023 Sep;201(2):183-192. doi: 10.1007/s10549-023-07017-8. Epub 2023 Jul 10. Breast Cancer Res Treat. 2023. PMID: 37428418 Free PMC article.
Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria.
Harmanen M, Klaavuniemi T, Sorigue M, Khan M, Prusila R, Kari E, Alanne E, Rajamäki A, Sunela K, Jukkola A, Jantunen E, Sancho JM, Ketola S, Kuitunen H, Selander T, Rönkä A, Kuittinen O. Harmanen M, et al. Among authors: ronka a. Hemasphere. 2023 Sep 7;7(10):e954. doi: 10.1097/HS9.0000000000000954. eCollection 2023 Oct. Hemasphere. 2023. PMID: 37693119 Free PMC article. No abstract available.
A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitors.
Tiainen S, Nurmela V, Selander T, Turunen P, Pasonen-Seppänen S, Kettunen T, Kuittinen O, Auvinen P, Rönkä A. Tiainen S, et al. Among authors: ronka a. BMC Cancer. 2023 Dec 4;23(1):1186. doi: 10.1186/s12885-023-11699-0. BMC Cancer. 2023. PMID: 38049762 Free PMC article.
29 results